{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colon%2FRectal+Cancer+Rectal+Cancer&page=14", "query": { "condition": "Colon/Rectal Cancer Rectal Cancer", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 2447, "total_pages": 245, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colon%2FRectal+Cancer+Rectal+Cancer&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colon%2FRectal+Cancer+Rectal+Cancer&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T13:28:10.468Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03712943", "title": "Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Metastatic Colorectal Cancer", "Colon Cancer" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2018-10-23", "completion_date": "2024-01-18", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-11-15T13:28:10.468Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03712943" }, { "nct_id": "NCT06562543", "title": "A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Fruquintinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2025-01-14", "completion_date": "2027-10-04", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-11-15T13:28:10.468Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06562543" }, { "nct_id": "NCT06152276", "title": "SafeHeal Diverting Ileostomy Pivotal Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Stoma Ileostomy" ], "interventions": [ { "name": "Diverting loop ileostomy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "SafeHeal Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2024-01-01", "completion_date": "2026-01-30", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-11-15T13:28:10.468Z", "location_count": 15, "location_summary": "Los Angeles, California • Miami, Florida • Tampa, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06152276" }, { "nct_id": "NCT02955940", "title": "An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Colorectal Cancer (CRC)", "Breast Cancer", "Lung Cancer" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2016-11-30", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-11-15T13:28:10.468Z", "location_count": 6, "location_summary": "Santa Monica, California • Louisville, Kentucky • Clifton Park, New York + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Clifton Park", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02955940" }, { "nct_id": "NCT05838768", "title": "Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers" ], "interventions": [ { "name": "HRO761", "type": "DRUG" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 123, "start_date": "2023-06-27", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-15T13:28:10.468Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05838768" }, { "nct_id": "NCT05453825", "title": "A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Triple Negative Breast Cancer", "Gastric Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "navicixizumab+paclitaxel", "type": "BIOLOGICAL" }, { "name": "navicixizumab+irinotecan", "type": "BIOLOGICAL" }, { "name": "navicixizumab monotherapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "OncXerna Theraputics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2022-08-05", "completion_date": "2024-12-15", "has_results": false, "last_update_posted_date": "2023-01-31", "last_synced_at": "2026-11-15T13:28:10.468Z", "location_count": 8, "location_summary": "Hot Springs, Arkansas • Los Angeles, California • Tampa, Florida + 5 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05453825" }, { "nct_id": "NCT02859415", "title": "Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Neoplasms", "Lung Neoplasms", "Mesothelioma", "Thymus Neoplasms", "Neoplasms, Germ Cell and Embryonal" ], "interventions": [ { "name": "Mithramycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-08-08", "completion_date": "2021-12-01", "has_results": true, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-11-15T13:28:10.468Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02859415" }, { "nct_id": "NCT02088333", "title": "Effectiveness of an mHealth Colorectal Cancer Screening Intervention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "mCRC intervention", "type": "BEHAVIORAL" }, { "name": "Healthy Lifestyles video", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "50 Years to 74 Years" }, "enrollment_count": 450, "start_date": "2014-06", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2022-02-17", "last_synced_at": "2026-11-15T13:28:10.468Z", "location_count": 6, "location_summary": "Advance, North Carolina • Mount Airy, North Carolina • Wilkesboro, North Carolina + 1 more", "locations": [ { "city": "Advance", "state": "North Carolina" }, { "city": "Mount Airy", "state": "North Carolina" }, { "city": "Wilkesboro", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02088333" }, { "nct_id": "NCT03043313", "title": "Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2017-06-23", "completion_date": "2023-11-02", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-11-15T13:28:10.468Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03043313" }, { "nct_id": "NCT04208958", "title": "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Melanoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "VE800", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Vancomycin Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Vedanta Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2020-01-23", "completion_date": "2023-02-23", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-11-15T13:28:10.468Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04208958" } ] }